Skip to content

ABOUT US

Advancing Cardiac DiagnosticsThrough Quantum Technology and AI

AMCG is an advanced medical device company pioneering next-generation cardiac diagnostics through the convergence of quantum sensing, medical technology, and artificial intelligence.

Using SQUID (Superconducting Quantum Interference Device) sensors, AMCG precisely detects ultra-weak magnetic signals generated by the heart and transforms them into meaningful cardiac information.

By integrating expertise in hardware, software, and medical science, AMCG continues to advance cardiac diagnostics and unlock new possibilities for quantum technology in healthcare.

FoundedMarch 2021
HeadquartersSeoul, South Korea

HISTORY

Our History

Backed by 30 years of full government support,

KRISS succeeded in developing the core technology of the magnetocardiography system.

  1. 2026
    • Designated as an Innovative Product (outstanding R&D)
    • Exhibited at CES 2026
    • Series C funding
  2. 2025
    • Developed MCG-F
    • Selected for the Materials and Components Technology Development Program
    • Grand Prize at the Seoul Metropolitan Government–Korea Financial Investment Association joint scale-up IR
  3. 2024
    • MCG-S received US FDA 510(k) clearance
    • Signed a Scale-up TIPS agreement
    • Series B funding
  4. 2022
    • MCG-S received MFDS medical device approval
    • Medical device GMP certification
    • ISO 13485 certification
    • Developed the helium reliquefaction system
  5. 2021
    • Founded AMCG
    • Developed the 96-channel MCG system
    • Venture company certification and corporate R&D center established
    • Series A funding